Dolcanatide

O=C([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC([C@H](N)CC(N)=O)=O)=O)N[C@](CSSC[C@@](NC([C@@H](NC([C@@H](NC1=O)C(C)C)=O)C)=O)([H])C(N[C@@](C(NCC(N2)=O)=O)([H])[C@H](O)C)=O)([H])C(N[C@H](C(N[C@@](C(N[C@](CSSC[C@H]2C(N[C@@H](C(O)=O)CC(C)C)=O)([H])C(N[C@H](C(N[C@H]1CC(N)=O)=O)C(C)C)=O)=O)([H])CC(C)C)=O)CCC(O)=O)=O

[1]Boulete IM, et al. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models. World J Gastroenterol. 2018 May 7;24 (17) :1888-1900.|[2]Shailubhai K, et al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015 Nov 6;6 (4) :213-22.